The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dose-modified abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC): The Princess Margaret Cancer Centre (PM) experience.
Raya Leibowitz-Amit
No relevant relationships to disclose
Eshetu G. Atenafu
No relevant relationships to disclose
Jo-An Seah
No relevant relationships to disclose
Arnoud J. Templeton
Honoraria - Janssen-Cilag
Francisco Emilio Vera-Badillo
No relevant relationships to disclose
Henry L. Solow
No relevant relationships to disclose
Jennifer J. Knox
No relevant relationships to disclose
Srikala S. Sridhar
Consultant or Advisory Role - Janssen-Ortho
Honoraria - Janssen-Ortho; Pfizer; Sanofi
Research Funding - Janssen-Ortho; Pfizer; Sanofi
Ian Tannock
No relevant relationships to disclose
Anthony Michael Joshua
Research Funding - Janssen-Ortho